Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aversa

Showing results (1211-1220 of 1,227) with videos related to

Pageof 123
Sort By:
European Urology Oncology|June 26, 2025
PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular SubtypesPasquale Rescigno, Maria Dolores Fenor de la Maza, Holly Tovey, et al.
Ebiomedicine|April 2, 2025
Computational fluid dynamics of small airway disease in chronic obstructive pulmonary diseaseYousry K Mohamady, Vincent Geudens, Charlotte De Fays, et al.
American Journal of Respiratory and Critical Care Medicine|August 13, 2025
Distinct Morphological Types of Small Airway Obstructions in Smokers with Emphysema and End-Stage COPDVincent Geudens, Charlotte De Fays, Lynn Willems, et al.
Haematologica|February 2, 2015
Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study)Morena Caira, Anna Candoni, Luisa Verga, et al.
Trials|November 5, 2023
Lung UltrasouNd Guided surfactant therapy in preterm infants: an international multicenter randomized control trial (LUNG study)Iuri Corsini, Javier Rodriguez-Fanjul, Francesco Raimondi, et al.
The European Respiratory Journal|July 9, 2026
Lung Transplantation for Pulmonary Alveolar Proteinosis - a Retrospective International Multi-Center AnalysisStefan Schwarz, Helmut Prosch, Erdal Yekeler, et al.
Journal of Medicinal Chemistry|May 31, 2017
Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant CancersGisele A Nishiguchi, Alice Rico, Huw Tanner, et al.
Nature|October 16, 2023
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistanceChristina Guo, Adam Sharp, Bora Gurel, et al.
Frontiers in Immunology|October 5, 2023
Iatrogenic air embolism: pathoanatomy, thromboinflammation, endotheliopathy, and therapiesPhillip L Marsh, Ernest E Moore, Hunter B Moore, et al.
Journal of Medicinal Chemistry|May 7, 2019
Design and Discovery of <i>N</i>-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the ClinicSavithri Ramurthy, Benjamin R Taft, Robert J Aversa, et al.
Pageof 123

Showing results (1211-1220 of 1,227) with videos related to

Sort By:
Pageof 123
European Urology Oncology|June 26, 2025
PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular SubtypesPasquale Rescigno, Maria Dolores Fenor de la Maza, Holly Tovey, et al.
Ebiomedicine|April 2, 2025
Computational fluid dynamics of small airway disease in chronic obstructive pulmonary diseaseYousry K Mohamady, Vincent Geudens, Charlotte De Fays, et al.
American Journal of Respiratory and Critical Care Medicine|August 13, 2025
Distinct Morphological Types of Small Airway Obstructions in Smokers with Emphysema and End-Stage COPDVincent Geudens, Charlotte De Fays, Lynn Willems, et al.
Haematologica|February 2, 2015
Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study)Morena Caira, Anna Candoni, Luisa Verga, et al.
Trials|November 5, 2023
Lung UltrasouNd Guided surfactant therapy in preterm infants: an international multicenter randomized control trial (LUNG study)Iuri Corsini, Javier Rodriguez-Fanjul, Francesco Raimondi, et al.
The European Respiratory Journal|July 9, 2026
Lung Transplantation for Pulmonary Alveolar Proteinosis - a Retrospective International Multi-Center AnalysisStefan Schwarz, Helmut Prosch, Erdal Yekeler, et al.
Journal of Medicinal Chemistry|May 31, 2017
Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant CancersGisele A Nishiguchi, Alice Rico, Huw Tanner, et al.
Nature|October 16, 2023
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistanceChristina Guo, Adam Sharp, Bora Gurel, et al.
Frontiers in Immunology|October 5, 2023
Iatrogenic air embolism: pathoanatomy, thromboinflammation, endotheliopathy, and therapiesPhillip L Marsh, Ernest E Moore, Hunter B Moore, et al.
Journal of Medicinal Chemistry|May 7, 2019
Design and Discovery of <i>N</i>-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the ClinicSavithri Ramurthy, Benjamin R Taft, Robert J Aversa, et al.
Pageof 123